Abstract: Provided is a microswitch including a first electrode, a second electrode, and a porous coordination polymer conductor, in which the porous coordination polymer conductor is represented by the following Formula (1), and a metal forming the first electrode and a metal forming the second electrode have different oxidation-reduction potentials, [MLx]n(D)y??(1), where M represents a metal ion selected from group 2 to group 13 elements in a periodic table, L represents a ligand that has two or more functional groups capable of coordination to M in a structure of L and is crosslinkable with two M's, D represents a conductivity aid that includes no metal element, x represents 0.5 to 4 and y represents 0.0001 to 20 with respect to x as 1, n represents the number of repeating units of a constituent unit represented by [MLx], and n represents 5 or more.

Abstract: This application provides a method for preparing human cell-derived microcells from human cells comprising DNA of interest, comprising: a step of culturing human cells in a medium containing at least one micronucleus inducer selected from the group consisting of microtubule polymerization inhibitors (excepting colcemid), microtubule depolymerization inhibitors, and spindle checkpoint inhibitors, thereby to produce human cell-derived microcells; and a step of collecting human cell-derived microcells comprising the DNA of interest, and a method for preparing human cells comprising DNA of interest by use of the method, which can be also applied to non-human animal cells.

Abstract: The present application provides: a method for producing human induced pluripotent stem (iPS) cells comprising an exogenous chromosome having a DNA of interest using the MMCT method; and a method for expressing the exogenous gene in the human iPS cells prepared by the method for producing human iPS cells, or in undifferentiated or differentiated cells derived from the human iPS cells induced to differentiate from the human iPS cells.

Abstract: A mouse artificial chromosome vector is stable in rodent cells, tissues, and/or individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from mouse chromosome 10 and mouse chromosome 16. A cell or a non-human animal may include the vector. The vector may be used for producing proteins and human antibodies.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: An object of the present invention is to provide a layer for suppressing permeation of soil moisture that has a low environmental load and can be easily constructed, and a method of forming the same. The method of forming a layer for suppressing permeation of soil moisture comprises a step of spraying coagulant for a natural rubber latex over a target soil and then spraying a natural rubber latex over the target soil, and repeating the step twice or more.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: A mental illness determination device includes a face change information acquisition unit and a mental illness determination unit. The face change information acquisition unit is configured to acquire face change information indicating a time-series change in face data of a subject when emotional stimulation information for stimulating any sense or any combination of senses among an auditory sense, an olfactory sense, a gustatory sense, a tactile sense, and a somatic sensation of the subject to change emotion, and is divided into positive information for increasing comfort and negative information for decreasing comfort is provided to the subject. The mental illness determination unit is configured to determine a state of mental illness of the subject on the basis of the face change information.

Abstract: An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: This application provides: a nucleic acid construct characterized by comprising, in a mammalian artificial chromosome vector, a DNA sequence of interest, a matrix attachment region, and a replication origin, and by using for high expression of the DNA; a mammalian cell comprising the nucleic acid construct; and a method for high production of a protein encoded by the DNA of interest in the mammalian cell.

Abstract: The present invention provides fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity. The present invention also provides a method for producing fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity and a method for producing Tyr-Pro, each of which is characterized by comprising fermenting milk with a mushroom.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: The present invention aims at providing a disposable diaper having excellent maintainability of a surface space and capable of being easily produced.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid, N-methyl-2-pyrrolidone and a fluoride; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid and N-methyl-2-pyrrolidone; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.

Abstract: According to an aspect, a testing instrument that is used for testing an airway protection function includes: a pipe portion continuous from an inlet port to an outlet port, the pipe portion having a plurality of holes penetrating the pipe portion from an outer surface of the pipe portion to an inner surface of the pipe portion, the holes being provided for guiding a reagent gas mixture to the inside of the pipe portion; and a guide portion covering all of the holes to form a closed space and guiding the reagent gas mixture to the closed space from an inflow port.

Abstract: To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.

Abstract: In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.

Abstract: The method for detoxifying asbestos disclosed here includes: preparing an asbestos-containing substance that contains at least one type of asbestos; preparing an asbestos treatment agent that contains a mineral acid and N-methyl-2-pyrrolidone; and bringing the asbestos-containing substance into contact with the asbestos treatment agent so as to detoxify asbestos in the asbestos-containing substance. Due to this configuration, asbestos in the asbestos-containing substance can be favorably detoxified.